Six Pot Stocks - AGH, CAN, AC8, BDA, BOT and EXL

  • Jan 26, 2019 AEDT
  • Team Kalkine
Six Pot Stocks - AGH, CAN, AC8, BDA, BOT and EXL

As the legalization of cannabis is taking place across many regions in the world, it is the right time to look at cannabis pot stocks. Though the returns on pot stocks have not been the best in 2018, the market sees upside potential for cannabis stocks this year, with many companies entering this profitable industry.

However, investors need to be cautious while picking marijuana stocks.

ALTHEA GROUP HOLDINGS LIMITED (ASX: AGH) – The company has signed an agreement with Cannabis Access Clinics as it reached the milestone of 300 patients with 86 registered Healthcare Professionals now prescribing Althea products throughout Australia. Cannabis Access Clinics runs one of the region’s largest medicinal cannabis clinic networks. With over 1,100 products dispensed by pharmacies throughout Australia to date, the milestone signifies the company’s growing importance in Australia’s medicinal cannabis market. The stock price of Althea went up by 9.259% on January 25, 2019, to close at $0.295 with a market cap of $54.89 million. 

CANN GROUP LIMITED (ASX: CAN) – The company has continued to build a platform that will generate shareholder value over the long term and will generate sustainable profits. The company has worked to maintain its various licenses and permits. These licenses were to import and export cannabis genetics and medicinal cannabis products. The company continues to invest in expanded capacity, and at Southern and Northern facilities additional works were carried out. Approximately $78 million was provided by a strongly supported capital raising at the end of last year. The stock price of Cann went down by 2.643% on January 25, 2019, to close at $2.210 with a market cap of $317.13 million.


The company has announced the completion of the acquisition of research and development facility of 7,300 m in Perth. Supporting the development, the facility will focus on the company’s cannabinoid pharmaceutical product pipeline. The company is set to further invest capital of up to $6 million over time after the R&D facility was purchased for $5.25 million. Cash on hand which was more than $40 million before the acquisition will be fully funded by the company for acquisition and upgrade costs. The stock price of Auscann went up by 3.15% on January 25, 2019, to close at $0.655 with a market cap of $196.27 million.


The company recently provided the quarterly update with product sales comprising of $766,000. The company has achieved record revenue of $1.22m for the quarter which represents a 260% increase on Q1 FY2019 and 129% on the corresponding prior period. Allowing the company to recover some costs from its Phase I Clinical Medicinal Cannabis Trial, the revenue for the quarter also included a net R&D tax rebate of $453,000. Across coming quarters, the company remains well positioned to continue its international expansion and sales growth. The stock price of BOD Australia traded flat on January 25, 2019, to trade at $0.460 with a market cap of $31.92 million.

BOTANIX PHARMACEUTICALS LTD (ASX: BOT) – The company has recently announced the successful completion of its Investigator’s Meeting for the BTX 1204 Phase 2 atopic dermatitis clinical study with attendees including investigating dermatologists and study site coordinators. The BTX 1204 Phase 2 study is expected to be fully recruited in Q3 CY2019 and is fully funded. Regarding the data from the completed Phase 1b atopic dermatitis patient study, the feedback is positive from the investigator’s meeting. For its BTX 1204 Phase 2 atopic dermatitis study the company lately announce the receipt of ethics approval. The stock price of BOT traded up by 5.814% on January 25, 2019, to close at $0.091 with a market cap of $65.14 million.


The company has recently announced that Elixinol branded cannabidiol (CBD) products are now available in the New Zealand market on a prescription basis. With first prescription being successfully shipped, Elixinol branded products are now available to patients in the New Zealand market. The company’s topicals, branded capsules, and tinctures including liposomes for import into New Zealand meet the required standard. The company announces Mr. Ron Dufficy as Chief Financial Officer & Company Secretary. The stock price of EXL Australia traded up by 2.875% on January 25, 2019, to close at $3.220 with a market cap of $389.84 million.


This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.


All pictures are copyright to their respective owner(s) does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.


There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK